Regulation of endothelial nitric oxide synthase and asymmetric dimethylarginine by matrine attenuates isoproterenol-induced acute myocardial injury in rats

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 8, 2012, Pages 1107-1118

  Li, Xiaobing ^a   Wang, Xiao ^a,b   Guo, Yafang ^a   Deng, Ning ^a,b   Zheng, Ping ^a,b   Xu, Qingbin ^b,d   Wu, Yang ^a,c   Dai, Guidong ^b,c  

^a NINGXIA MEDICAL UNIVERSITY   (China)

^b Ningxia Engineering and Technology Research Center for Modernization of Hui Medicine   (China)

^c Ningxia Research Institute of Medicine and Pharmacy   (China)

^d AFFILIATED HOSPITAL OF NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Asymmetric dimethylarginine; Endothelial nitric oxide synthase; Isoproterenol; Matrine; Myocardial ischaemia

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CATECHOL METHYLTRANSFERASE; DIMETHYLARGININASE; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOGEN SYNTHASE KINASE 3BETA; ISOPRENALINE; MATRINE; N(G),N(G) DIMETHYLARGININE; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 1; PROTEIN KINASE B; SERINE; UNCLASSIFIED DRUG;

ACUTE DISEASE; AMINO ACID BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; MALE; N(G),N(G) DIMETHYLARGININE BLOOD LEVEL; NONHUMAN; PROTEIN EXPRESSION; RAT; TREATMENT DURATION;

ALKALOIDS; AMIDOHYDROLASES; ANIMALS; ARGININE; CATECHOL O-METHYLTRANSFERASE; GLYCOGEN SYNTHASE KINASES; HEART VENTRICLES; ISOPROTERENOL; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NECROSIS; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PHYTOTHERAPY; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLIZINES; RATS; RATS, SPRAGUE-DAWLEY; SOPHORA;

EID: 84863723407     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01502.x     Document Type: Article

References (42)

1. Aronow WS,. Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure. Cardiol Rev 2006; 14: 108-124. (Pubitemid 44350382)
2. Whellan DJ,. Heart failure disease management: implementation and outcomes. Cardiol Rev 2005; 13: 231-239. (Pubitemid 41197251)
3. Rona G,. Catecholamine cardiotoxicity. J Mol Cell Cardiol 1985; 17: 291-300.
4. Anandan R, et al,. Protective effect of n-3 polyunsaturated fatty acids concentrate on isoproterenol-induced myocardial infarction in rats. Prostaglandins Leukot Essent Fatty Acids 2007; 76: 153-158. (Pubitemid 46366655)
5. Karthikeyan K, et al,. Cardioprotective effect of grape seed proanthocyanidins on isoproterenol-induced myocardial injury in rats. Int J Cardiol 2007; 115: 326-333. (Pubitemid 46185633)
6. Sampath PD, Kannan V,. Mitigation of mitochondrial dysfunction and regulation of eNOS expression during experimental myocardial necrosis by alpha-mangostin, a xanthonic derivative from Garcinia mangostana. Drug Chem Toxicol 2009; 32: 344-352.
7. Xu CQ, et al,. Comparison of the anti-arrhythmic effects of matrine and berbamine with amiodarone and RP58866. Yao Xue Xue Bao 2004; 39: 691-694.
8. Zhang YJ, et al,. Effect of matrine and carvedilol on collagen and MMPs activity of hypertrophy myocardium induced by pressure overload. J Zhejiang Univ Sci B 2006; 7: 245-250.
9. Li Y, et al,. Matrine induces apoptosis in angiotensin II-stimulated hyperplasia of cardiac fibroblasts: effects on Bcl-2/Bax expression and caspase-3 activation. Basic Clin Pharmacol Toxicol 2007; 101: 1-8. (Pubitemid 46934645)
10. Zheng J, et al,. Relaxant effects of matrine on aortic smooth muscles of guinea pigs. Biomed Environ Sci 2009; 22: 327-332.
11. Li X, et al,. Cardioprotective effect of matrine on isoproterenol-induced cardiotoxicity in rats. J Pharm Pharmacol 2010; 62: 514-520.
12. Gaballa MA, et al,. Effects of endothelial and inducible nitric oxide synthases inhibition on circulatory function in rats after myocardial infarction. Cardiovasc Res 1999; 42: 627-635. (Pubitemid 29298131)
13. Gao F, et al,. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 2002; 105: 1497-1502. (Pubitemid 34263284)
14. Matsui T, Rosenzweig A,. Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol 2005; 38: 63-71. (Pubitemid 40038652)
15. Krenek P, et al,. Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function. Eur J Heart Fail 2009; 11: 140-146.
16. Lin Y, et al,. L-arginine inhibits isoproterenol-induced cardiac hypertrophy through nitric oxide and polyamine pathways. Basic Clin Pharmacol Toxicol 2008; 103: 124-130. (Pubitemid 352019727)
17. Massion PB, Balligand JL,. Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): lessons from genetically modified mice. J Physiol 2003; 546: 63-75.
18. Landmesser U, et al,. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004; 110: 1933-1939. (Pubitemid 39331904)
19. Ozaki M, et al,. Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion. Circ J 2002; 66: 851-856. (Pubitemid 34988223)
20. Böger RH, et al,. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119: 1592-1600.
21. Böger RH, et al,. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009; 60: 481-487.
22. Feng Q, et al,. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res 1998; 37: 667-675. (Pubitemid 28231161)
23. Li D, et al,. Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats. Can J Physiol Pharmacol 2007; 85: 783-789. (Pubitemid 350144738)
24. De Gennaro Colonna V, et al,. Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats. Eur J Pharmacol 2007; 557: 178-185. (Pubitemid 46186290)
25. Richir MC, et al,. Low arginine/asymmetric dimethylarginine ratio deteriorates systemic hemodynamics and organ blood flow in a rat model. Crit Care Med 2009; 37: 2010-2017.
26. Loh HK, et al,. Effects of thalidomide on isoprenaline-induced acute myocardial injury: a haemodynamic, histopathological and ultrastructural study. Basic Clin Pharmacol Toxicol 2007; 100: 233-239. (Pubitemid 46435082)
27. Zhou R, et al,. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. Eur J Pharmacol 2008; 586: 244-250.
28. Dimmeler S, et al,. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-605.
29. Mount PF, et al,. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 2007; 42: 271-279. (Pubitemid 46135596)
30. Wolfrum S, et al,. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004; 24: 1842-1847. (Pubitemid 39350301)
31. Haq S, et al,. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 2000; 151: 117-130.
32. Nishihara M, et al,. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol 2006; 291: 748-755.
33. Gross ER, et al,. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 2004; 94: 960-966. (Pubitemid 38490074)
34. Song JQ, et al,. Activation of Akt/GSK-3beta signaling pathway is involved in intermedin(1-53) protection against myocardial apoptosis induced by ischemia/reperfusion. Apoptosis 2009; 14: 1061-1069.
35. Pei Y, et al,. Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. Eur J Pharmacol 2011; 62: 514-520.
36. Teerlink T,. ADMA metabolism and clearance. Vasc Med 2005; 10: 73-81.
37. Böger RH, et al,. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atherosclerosis 2003; 10: 1-3. (Pubitemid 38234488)
38. Pawlak MR, et al,. Arginine N-methyltransferase 1 is required for early postimplantation mouse development, but cells deficient in the enzyme are viable. Mol Cell Biol 2000; 20: 4859-4869. (Pubitemid 30396132)
39. Leiper JM, et al,. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343: 209-214. (Pubitemid 29473897)
40. Gray GA, et al,. Immunolocalisation and activity of DDAH I and II in the heart and modification post-myocardial infarction. Acta Histochem 2010; 112: 413-423.
41. Conolly ME, et al,. Metabolism of isoprenaline in dog and man. Br J Pharmacol 1972; 46: 458-472.
42. Stanton HC, et al,. Effects of monoamine oxidase inhibitors on isoproterenol-induced cardiomegaly in rats. Toxicol Appl Pharmacol 1970; 16: 256-263.